Completed PHASE1 INTERVENTIONAL 3-arm NCT03583489

Study of APD421 With and Without Ondansetron

A Randomised, Double-blind, Placebo-controlled, Crossover Study in Healthy Adult Subjects to Investigate the Effect of Intravenous APD421, With and Without Ondansetron, on Cardiac Conduction

Sponsor: Acacia Pharma Ltd

Conditions Postoperative Nausea and Vomiting

Interventions APD421 Ondansetron Placebo

Updated 6 times since 2018 Last updated: Sep 28, 2018 Started: Jul 17, 2018 Primary completion: Aug 13, 2018 Completion: Aug 13, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Postoperative Nausea and Vomiting, this trial is completed. The trial is conducted by Acacia Pharma Ltd and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Enrolling By Invitation → Completed
Sep 2018 — Nov 2018 [monthly]

Enrolling By Invitation PHASE1

▶ Show 1 earlier version

Aug 2018 — Sep 2018 [monthly]

Enrolling By Invitation PHASE1

First recorded

Jul 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acacia Pharma Ltd

Data source: Acacia Pharma Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom